Literature DB >> 19699192

Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay.

Benjamin Dieplinger1, James L Januzzi, Martin Steinmair, Christian Gabriel, Werner Poelz, Meinhard Haltmayer, Thomas Mueller.   

Abstract

BACKGROUND: The protein ST2 is a member of the interleukin-1 receptor family. Blood concentrations of the soluble isoform of ST2 (sST2) are increased in inflammatory diseases and in heart disease and are considered a prognostic marker in both. The aim of this study was the analytical and clinical evaluation of the novel Presage ST2 assay for the determination of sST2 in human plasma.
METHODS: We evaluated precision and linearity of the assay, analyte stability, and biological variability, determined reference values, performed a method comparison with an established ELISA, and quantified sST2 concentrations in various diseases.
RESULTS: Within-run and total coefficients of variation were <2.5% and <4.0%. The method was linear across the whole measurement range of the assay. The analyte was stable for 48 h at room temperature, for 7 days at 4 degrees C, and for at least 2 months at -20 degrees C and -80 degrees C. The reference change value for healthy individuals was 30%. Age-independent reference values were 3-28 U/mL in males, and 2-16 U/mL in females. The method comparison revealed a high proportional bias. sST2 plasma concentrations were increased modestly in heart failure and moderately in pneumonia and chronic obstructive pulmonary disease. Patients with sepsis exhibited highly elevated sST2 values. In patients with chronic renal disease, however, there was no difference compared to healthy individuals.
CONCLUSION: The Presage ST2 assay meets the needs of quality specifications of laboratory medicine. The results of the clinical assay evaluation are novel with respect to sST2 in various diseases and should initiate further studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699192     DOI: 10.1016/j.cca.2009.08.010

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  69 in total

Review 1.  ST2: a novel remodeling biomarker in acute and chronic heart failure.

Authors:  Ravi V Shah; James L Januzzi
Journal:  Curr Heart Fail Rep       Date:  2010-03

2.  Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling.

Authors:  Jennifer E Ho; Wei-Yu Chen; Ming-Huei Chen; Martin G Larson; Elizabeth L McCabe; Susan Cheng; Anahita Ghorbani; Erin Coglianese; Valur Emilsson; Andrew D Johnson; Stefan Walter; Nora Franceschini; Christopher J O'Donnell; Abbas Dehghan; Chen Lu; Daniel Levy; Christopher Newton-Cheh; Honghuang Lin; Janine F Felix; Eric R Schreiter; Ramachandran S Vasan; James L Januzzi; Richard T Lee; Thomas J Wang
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 3.  Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases.

Authors:  Rajesh Parsanathan; Sushil K Jain
Journal:  Metab Syndr Relat Disord       Date:  2019-10-16       Impact factor: 1.894

4.  The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects.

Authors:  D B Ojji; L H Opie; S Lecour; L Lacerda; O M Adeyemi; K Sliwa
Journal:  J Hum Hypertens       Date:  2014-01-09       Impact factor: 3.012

5.  Soluble ST2: a new and promising activity marker in ulcerative colitis.

Authors:  David Díaz-Jiménez; Lucía E Núñez; Caroll J Beltrán; Enzo Candia; Cristóbal Suazo; Manuel Alvarez-Lobos; María-Julieta González; Marcela A Hermoso; Rodrigo Quera
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

Review 6.  The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers.

Authors:  Marin Nishimura; Alison Brann; Kay-Won Chang; Alan S Maisel
Journal:  Curr Heart Fail Rep       Date:  2018-08

7.  Preoperative serum ST2 level predicts acute kidney injury after adult cardiac surgery.

Authors:  Kevin W Lobdell; Devin M Parker; Donald S Likosky; Michael Rezaee; Moritz Wyler von Ballmoos; Shama S Alam; Sherry Owens; Heather Thiessen-Philbrook; Todd MacKenzie; Jeremiah R Brown
Journal:  J Thorac Cardiovasc Surg       Date:  2018-04-11       Impact factor: 5.209

8.  Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study.

Authors:  Thomas J Wang; Kai C Wollert; Martin G Larson; Erin Coglianese; Elizabeth L McCabe; Susan Cheng; Jennifer E Ho; Michael G Fradley; Anahita Ghorbani; Vanessa Xanthakis; Tibor Kempf; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan; James L Januzzi
Journal:  Circulation       Date:  2012-08-20       Impact factor: 29.690

9.  Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study.

Authors:  Erin E Coglianese; Martin G Larson; Ramachandran S Vasan; Jennifer E Ho; Anahita Ghorbani; Elizabeth L McCabe; Susan Cheng; Michael G Fradley; Dana Kretschman; Wei Gao; George O'Connor; Thomas J Wang; James L Januzzi
Journal:  Clin Chem       Date:  2012-10-11       Impact factor: 8.327

10.  Soluble ST2 predicts elevated SBP in the community.

Authors:  Jennifer E Ho; Martin G Larson; Anahita Ghorbani; Susan Cheng; Ramachandran S Vasan; Thomas J Wang; James L Januzzi
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.